Fri, Jul 25, 2014, 5:29 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Alimera Sciences, Inc. (ALIM) Message Board

  • sdusablon sdusablon Dec 15, 2011 11:45 PM Flag

    When and if might Europe approve?

    Everyone is hearing all kinds of speculation about ALIM getting approved in Europe. Maybe by the end of 2011 or early 2012? If and when might it get the ok? Can this stock got to $4.00 if approved?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The answers to your questions are yes but the real question is When? When will it be approved and when can it go to 4 dollars or even 8 dollars? now, next month, next year?

      • 1 Reply to emtvans
      • Seeing some nice chunks on the bid side on Level II now. I am assuming the company has already sent their results to the MHRA (supposed to be end of last month) and are expecting a recommendation by end of year.

        Say it is delayed by the holidays, we should hear by early Jan. That's all that is required for this to go to $4 as Europe is not going to be swayed by politics/conflicts of interest (as in the case of FDA decision makers here).

        I am expecting European approval (95% probability) since there is already a product out there with the same compounds approved by the FDA.

    • Give it up already. You now have two CRL's and a mismanaged company on your hands. Assume the best possible scenario in which Europe approves and you still will be waiting months for revenues and earnings to manifest themselves. The market will not run the stock up prior to approval like the good ol days. Now it is show me the goods.

      Find a new stock and avoid beating this dead horse.

      bm

 
ALIM
5.80+0.04(+0.69%)Jul 25 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.